康诺亚-B(02162.HK)8月26日举行董事会会议考虑并批准中期业绩 康诺亚-B(02162.HK)完成配售2160万 股 净筹8.54亿港元 格隆汇8月14日丨康诺亚-B(02162.HK)宣布，公司将于2025年8月26日(星期二)举行董事会会议，藉以(其 中包括)考虑并批准公司及其附属公司截至2025年6月30日止六个月中期业绩及其发布，以及考虑派发中 期股息(如有)。 相关事件 ...

Keymed Biosciences Inc. 康諾亞生物醫藥科技有限公司 （於開曼群島註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2162） 香港，2025年8月14日 董事會召開日期 於本公告日期，董事會包括執行董事Bo CHEN博士、Changyu WANG博士及徐剛 博士；非執行董事陳奇先生、王閩川博士及劉逸倫先生；及獨立非執行董事王小 凡教授、柯楊教授及羅卓堅先生。 康諾亞生物醫藥科技有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司 將於2025年8月26日（星期二）舉行董事會會議，藉以（其中包括）考慮並批准本公 司及其附屬公司截至2025年6月30日止六個月中期業績及其發佈，以及考慮派發 中期股息（如有）。 承董事會命 康諾亞生物醫藥科技有限公司 董事長 Bo CHEN博士 ...

Market Overview - The Hang Seng Index closed at 25,613.67, up 2.58% for the day and 27.80% year-to-date[3] - The Hang Seng Tech Index rose to 5,630.78, increasing by 3.52% daily and 25.11% year-to-date[3] - The Nikkei 225 index closed at 43,274.67, with a daily increase of 1.30% and a year-to-date rise of 8.47%[3] Stock Performance Highlights - Alibaba's stock surged by 6%, while Tencent rose nearly 5%, reaching a four-year high, with Q2 2025 revenue up 15% year-on-year[9] - Tencent Music's shares increased over 15%, hitting a historical high following Tencent's strong earnings report[9] - Weimob Group's stock climbed over 6%, reaching a five-month high due to new partnerships enhancing its service capabilities[9] Sector Movements - Biopharmaceutical stocks remained active, with notable gains in innovative drug companies following the announcement of new drug approvals[9] - Broker stocks saw significant increases, with Shenwan Hongyuan Hong Kong up over 7% and Yao Cai Securities up over 6%[9] - Lithium battery stocks experienced a pullback, with Tianqi Lithium down 1.7%[9] U.S. Market Trends - Major U.S. indices closed higher, with the Nasdaq and S&P 500 reaching new historical closing highs[9] - Ethereum and Bitcoin hit new all-time highs, boosting cryptocurrency-related stocks significantly[9] Economic Indicators - The U.S. Federal Reserve is expected to lower interest rates, with predictions of a 50 basis point cut in September and three additional cuts throughout the year[12] - China's July social financing growth was lower than expected, with a total of 1.16 trillion yuan, and the M2 money supply grew by 8.8% year-on-year[14]

Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed Fund C, which has shown significant growth in recent months and has a strong portfolio in the healthcare sector [1][3]. - As of August 13, 2025, the latest net value of Zhongyin Innovation Medical Mixed Fund C is 2.1969 yuan, reflecting a growth of 3.87% [1]. - The fund has achieved a return of 15.09% over the past month, ranking 1008 out of 4699 in its category [1]. - Over the last six months, the fund's return is 86.76%, ranking 26 out of 4543 [1]. - Year-to-date, the fund has returned 85.33%, ranking 30 out of 4501 [1]. - The top ten stock holdings of the fund account for a total of 62.83%, with significant positions in companies such as Innovent Biologics (8.33%), Kelun-Biotech (8.15%), and Hengrui Medicine (8.08%) [1]. Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of June 30, 2025, it has a total scale of 2.686 billion yuan [1]. - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the investment industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2]. - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on management roles for other funds within the healthcare sector [2].

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drugs, biomedicine, and AI healthcare sectors, leading the market gains [1] - As of the report, the innovative drug ETF (159748) saw an intraday increase of 3.85%, with key stocks like Haikang rising over 10% and others like Innovent and Kelun increasing over 7% [1] - The Hong Kong Stock Connect medical ETF (159506) also experienced a rise of 3.20%, with stocks such as CanSino Biologics increasing over 8% and WuXi AppTec rising over 6% [1] Group 2 - On August 12, the National Healthcare Security Administration announced the preliminary review of 121 innovative drugs for inclusion in the commercial insurance innovative drug directory, which includes several PD-1 drugs and five domestically approved CAR-T therapies [1] - The announcement from the healthcare authority is expected to enhance the accessibility of payments and improve commercialization expectations for these "star products," potentially raising the valuation center for innovative drugs in the Hong Kong market [1] - Recent clarifications on brain-computer interface implementation and industrial goals are expected to boost expectations in high-end medical equipment, neuroregulation, and surgical robotics sectors [1] Group 3 - The innovative drug ETF (159748) closely tracks the SHS Innovative Drug Index (CSI: 931409), which selects listed companies engaged in the research, production, and sales of innovative drugs, focusing on high-quality securities in the pharmaceutical sector [1] - The Hong Kong Stock Connect medical ETF (159506) tracks the Hang Seng Hong Kong Stock Connect Healthcare Index (HSSCHI), which excludes companies with the lowest average R&D to revenue rankings over the past two years, emphasizing high R&D spending and innovative drug business proportions [2]

Core Viewpoint - The Hong Kong stock market showed a strong upward trend in the morning session, with the Hang Seng Technology Index leading the gains, reflecting a notable recovery in market sentiment [1] Group 1: Market Performance - The Hang Seng Index rose by 470 points, surpassing the 25,000 mark, with the Hang Seng Index, and the National Enterprises Index increasing by 1.88% and 1.86% respectively [1] - The Hang Seng Technology Index surged by 2.35%, indicating strong performance in the technology sector [1] Group 2: Sector Performance - Major technology stocks and large financial stocks (insurance, banks, brokers) collectively boosted the market, with Alibaba rising by 4.37%, and Meituan, Tencent, and Baidu each increasing by over 3% [1] - China’s brokerage stocks saw significant gains, with Guolian Minsheng rising nearly 8% [1] - Biopharmaceutical stocks experienced substantial increases, led by Kangnuo Ya, Geely Pharmaceutical, and Innovent Biologics in the innovative drug concept [1] Group 3: Investment Trends - Institutional investors are optimistic about Apple's additional investments in the U.S., which is expected to enhance the valuation of the Apple supply chain, leading to continued gains in Apple-related stocks [1] - Other sectors such as stablecoin-related stocks, Tesla-related stocks, military industry stocks, non-ferrous metal stocks, semiconductor stocks, aviation stocks, and oil stocks also saw upward movements [1] Group 4: Declining Sectors - Conversely, gaming stocks and paper industry stocks faced declines, with Galaxy Entertainment dropping by as much as 4% during the session [1] - Companies like Chenming Paper and Nine Dragons Paper also experienced downturns, while some sectors such as wind power, water services, and vocational education saw partial declines [1] - The overall market still had nearly 30 stocks with declines exceeding 10% [1]

Core Insights - The Hang Seng Healthcare Index (HSHCI) has shown a strong increase of 1.66%, with notable gains in constituent stocks such as Weigao (9.05%) and Innovent Biologics (4.41%) [3] - The Hang Seng Medical ETF (513060) has risen by 0.89%, with a recent price of 0.68 yuan, and has accumulated a 15.41% increase over the past month, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) has also increased by 1.63%, with significant contributions from stocks like Innovent Biologics and Kangtai Biologicals [5] Market Dynamics - The National Healthcare Security Administration has announced the preliminary review of 121 innovative drugs for inclusion in the commercial insurance innovative drug directory, which is expected to enhance payment accessibility and commercial expectations for these products [5][6] - The medical device sector is experiencing positive sentiment due to clear technological routes and industrialization goals for brain-computer interfaces, which are expected to boost high-end medical equipment and surgical robotics [6] Investment Trends - The innovative drug sector has seen significant year-to-date gains, leading to some profit-taking and short-term volatility, while the medical device sector is attracting marginal inflows due to favorable policies and industry trends [7] - Analysts suggest focusing on companies with strong cash flow and commercial certainty in the innovative drug space, while the medical device sector is recommended for its policy-driven opportunities [8] ETF Performance - The Hang Seng Medical ETF has a current scale of 73.29 billion yuan, ranking in the top third among comparable funds, with a net value increase of 39.30% over the past two years [11][12] - The ETF has demonstrated a maximum monthly return of 28.34% since inception, with an average monthly return of 7.42% [12] - The Hang Seng Medical ETF has a tracking error of 0.060%, the highest precision among comparable funds, and its latest P/E ratio is 29.88, indicating a historical low valuation [16] Fund Characteristics - The Hong Kong Innovative Drug Selection ETF (520690) has seen a significant increase in scale, with a recent size growth of 27.29 million yuan, ranking in the top half among comparable funds [18] - The ETF has achieved a new high in shares at 404 million, with continuous net inflows over the past four days [19] - The management fee for both ETFs is 0.50%, with the Hong Kong Innovative Drug Selection ETF having the lowest custody fee at 0.10% among comparable funds [21]

Group 1 - The core viewpoint of the article highlights the performance of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has a latest net value of 0.7909 yuan, reflecting a decline of 1.25% [1] - The fund has shown a one-month return of 14.91%, ranking 312 out of 4699 in its category; a six-month return of 60.28%, ranking 58 out of 4543; and a year-to-date return of 61.47%, ranking 78 out of 4501 [1] - The fund's top ten stock holdings account for a total of 61.79%, with significant positions in companies such as Sangfor Technologies (10.07%), Innovent Biologics (8.94%), and Kelun Pharmaceutical (8.71%) [1] Group 2 - The Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A was established on August 21, 2020, and as of June 30, 2025, it has a total scale of 1.922 billion yuan [1] - The fund manager, Zheng Lei, has a background in social medicine and health management from Fudan University and has held various positions in the finance and investment sectors, including roles at Guotai Junan Securities and China Oceanwide Fund Management [2]

Core Viewpoint - The recent pullback in the innovative drug sector does not indicate a peak, as the underlying logic differs from previous market cycles, particularly the 2021 bubble [2][3]. Group 1: Current Market Conditions - The current rise in innovative drugs is supported by strong fundamentals, contrasting with the previous bubble driven by capital [4][5]. - Key drivers include the ability to generate revenue from overseas markets, gradual improvement in domestic drug consumption capacity, favorable policy changes, and advancements in technology [5][6][7]. - The Chinese market is expected to see a significant increase in the approval speed for innovative drugs, with the average approval time reduced from 24 months to 12 months [6]. Group 2: Investment Opportunities - The innovative drug market is likely to experience a long-term trend supported by various factors, including engineering talent, policy benefits, technological breakthroughs, and capital support [7]. - Companies in the sector face challenges in realizing their pipeline values, necessitating careful evaluation of current market valuations against potential future values [8][11]. - The market has shifted from negative expectations to normal expectations, leading to substantial price increases for many companies that were previously undervalued [9][10]. Group 3: Specific Company Analysis - For instance, He Yu Pharmaceutical has a market cap of approximately 70 billion HKD, with cash reserves of 23 billion RMB and pipeline values potentially exceeding 40 billion RMB [12][14]. - The company's lead pipeline candidate, Pimicotinib, has high market expectations, with projected peak sales exceeding 2 billion USD [12][14]. - Other companies in the sector exhibit similar characteristics, where short-term price increases may obscure the true intrinsic value of their businesses [17]. Group 4: Future Trends and Strategies - The market is expected to transition from a broad-based rally to a more differentiated performance, emphasizing the importance of identifying companies with strong fundamentals [18]. - Business Development (BD) will continue to be a critical factor, with companies focusing on reliable technologies and partnerships to drive growth [18][19]. - Pre-commercial companies are also seen as attractive investments, as their valuations can significantly increase upon achieving commercialization milestones [23][24]. Group 5: Industry Outlook - The Chinese innovative drug industry is undergoing a critical transformation, with improved R&D capabilities and capital efficiency, comparable to strong sectors like photovoltaics and new energy [25].